1. Океанов, А. Е. Статистика онкологических заболеваний в Республике Беларусь (2004-2013) / А. Е. Океанов, П. И. Моисеев, Л. Ф. Левин. - Минск : Респ. науч.-практ. центр онкологии и мед. радиологии, 2014. - 382 с.
2. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials / R. J. Sylvester [et al.] // Eur. Urol. - 2006. - Vol. 49, N 3. - P. 466-477. https://doi.org/10.1016/j.eururo.2005.12.031
3. Esteller, M. Epigenetic gene silencing in cancer:the DNA hypermethylome / M. Esteller // Human Mol. Genetics. - 2007. - Vol. 16, N R1. - P. R50-R59. https://doi.org/10.1093/hmg/ddm018
4. Jones, P. A. The epigenomics of cancer / P. A. Jones, S. B. Baylin // Cell. - 2007. - Vol. 128, N 4. - P. 683-692. https://doi. org/10.1016/j.cell.2007.01.029
5. Enokida, H. Epigenetics in bladder cancer / H. Enokida, M. Nakagawa // Intern. J. Clin. Oncol. - 2008. - Vol. 13, N 4. - P. 298-307. https://doi.org/10.1007/s10147-008-0811-1
6. DNA methylation alterations in urothelial carcinoma / A. Neuhausen [et al.] // Cancer Biol. Ther. - 2006. - Vol. 5, N 8. - P. 993-1001.
7. Phe, V. Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract / V. Phé, O. Cussenot, M. Rouprȇt // BJU Intern. - 2009. - Vol. 104, N 7. - P. 896-901. https://doi.org/10.1111/j.1464-410X.2009.08696.x
8. Prevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors / G. Dominguez [et al.] // Mutation Res./Fundamental and Molecular Mechanisms of Mutagenesis. - 2003. - Vol. 530, N 1-2. - P. 9-17. https://doi. org/10.1016/S0027-5107(03)00133-7
9. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma / J. W. Catto [et al.] // J. Clin. Oncol. - 2005. - Vol. 23, N 13. - Р. 2903-2910. https://doi.org/10.1200/JCO.2005.03.163
10. Methylation of tumor suppressor genes in a novel panel predicts clinical outcome in paraffin-embedded bladder tumors / R. García-Baquero [et al.] // Tumour Biology. - 2014. - Vol. 35, N 6. - P. 5777-5786. https://doi.org/10.1007/s13277-014-1767-6
11. p16INK4A and p14ARF gene promoter hypermethylation as prognostic biomarker in oral and oropharyngeal squamous cell carcinoma: a review / A. Al-Kaabi [et al.] // Disease Markers. - 2014. - Vol. 2014. - Art. 260549. https://doi.org/ 10.1155/2014/260549
12. Kopnin, B. P. Targets of oncogenes and tumor suppressors: key for understanding basic mechanisms of carcinogenesis / B. P. Kopnin // Biochemistry. - 2000. - Vol. 65, N 1. - P. 2-27.
13. Mitra, A. P. Molecular pathogenesis and diagnostics of bladder cancer / A. P. Mitra, R. J. Cote // Annu. Rev. Pathol.: Mech. Dis. - 2009. - Vol. 4, N 1. - P. 251-285. https://doi.org/10.1146/annurev.pathol.4.110807.092230
14. Tissue inhibitor of metalloproteinases-3 promoter methylation is an independent prognostic factor for bladder cancer / M. O. Hoque [et al.] // J. Urol. - 2008. - Vol. 179, N 2. - P. 743-747. https://doi.org/10.1016/j.juro.2007.09.019
15. Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma / M. Krajnović [et al.] // Med. Oncol. - 2013. - Vol. 30, N 1. - P. 441. https://doi.org/10.1007/s12032-012-0441-3
16. Peng, D. The relationship between P16 gene promoter methylation and gastric cancer: a meta-analysis based on Chinese patients / D. Peng, H. Zhang, G. Sun // J. Cancer Res. Ther. - 2014. - Vol. 10, N 8, suppl. - P. C292-C295. https://doi.org/ 10.4103/0973-1482.151535
17. Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma / A. K. ElNaggar [et al.] // Am. J. Pathol. - 1997. - Vol. 151, N 6. - P. 1767-1774.
18. Promoter methylation of MLH1, PMS2, MSH2 and p16 is a phenomenon of advanced-stage HCCs / I. Hinrichsen [et al.] // PLoS One. - 2014. - Vol. 9, N 1. - P. e84453. https://doi.org/10.1371/journal.pone.0084453
19. Aberrant DNA methylation of P16, MGMT, and hMLH1 genes in combination with MTHFR C677T genetic polymorphism in esophageal squamous cell carcinoma / J. Wang [et al.] // Cancer Epidemiol. Biomarkers Prevention. - 2008. - Vol. 17, N 1. - Р. 118-125. https://doi.org/10.1158/1055-9965.EPI-07-0733
20. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers / K. E. Bachman [et al.] // Cancer Res. - 1999. - Vol. 59, N 4. - P. 798-802.
21. Aberrant promoter methylation of multiple genes in non-small cell lung cancers / S. Zöchbauer-Müller [et al.] // Cancer Res. - 2001. - Vol. 61, N 1. - P. 249-255.
22. Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events/ R. R. Serizawa [et al.] // Intern.J. Cancer. - 2011. - Vol. 129, N 1. - P. 78-87. https://doi.org/10.1002/ ijc.25651
23. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection / M. O. Hoque [et al.]// JNCI: J. Natl. Cancer Inst. - 2006. - Vol. 98, N 14. - P. 996-1004. https://doi.org/10.1093/jnci/djj265
24. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients / M. G. Friedrich [et al.] // Clin. Cancer Res. - 2004. - Vol. 10, N 22. - P. 7457-7465. https://doi.org/10.1158/1078-0432.CCR-04-0930
25. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma / M. G. Friedrich [et al.] // Eur. J. of Cancer. - 2005. - Vol. 41, N 17. - P. 2769-2778. https://doi.org/10.1016/j.ejca.2005.07.019
26. Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence / I. Orlow [et al.] // Am. J. Pathol. - 1999. - Vol. 155, N 1. - P. 105-113. https://doi.org/10.1016/S0002-9440(10)65105-X
27. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer / K. Kawamoto [et al.] // Biochem. Biophys. Res. Commun. - 2006. - Vol. 339, N 3. - Р. 790-796. https://doi.org/10.1016/j.bbrc.2005.11.072
28. Comprehensive molecular characterization of urothelial bladder carcinoma / J. N. Weinstein [et al.] // Nature. - 2014. - Vol. 507, N 7492. - P. 315-322. https://doi.org/10.1038/nature12965
29. The relationship between promoter methylation of p16 gene and bladder cancer risk: a meta-analysis / D. Qi [et al.] // Intern. J. Clin. Exp. Med. - 2015. - Vol. 8, N 11. - P. 20701-20711.
30. Carcinogen exposure and gene promoter hypermethylation in bladder cancer / C. J. Marsit [et al.] // Carcinogenesis. - 2006. - Vol. 27, N 1. - P. 112-116. https://doi.org/10.1093/carcin/bgi172
31. Molecular classification of non-muscle-invasive bladder cancer (pTa low-grade, pT1 low-grade, and pT1 high-grade subgroups) using methylation of tumor-suppressor genes / R. Sacristan [et al.] // J. Mol. Diagn. - 2014. - Vol. 16, N 5. - P. 564- 572. https://doi.org/10.1016/j.jmoldx.2014.04.007
32. Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guérin response in patients with T1G3 high-risk bladder tumours / M. Agundez [et al.] // Eur. Urol. - 2011. - Vol. 60, N 1. - P. 131-140. https://doi. org/10.1016/j.eururo.2011.04.020
33. Promoter hypermethylation identifies progression risk in bladder cancer / D. R. Yates [et al.] // Clin. Cancer Res. - 2007. - Vol. 13, N 7. - P. 2046-2053. https://doi.org/10.1158/1078-0432.CCR-06-2476
34. DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach / V. Casadio [et al.] // J. Exp. Clin. Cancer Res. - 2013. - Vol. 32. - P. 94. https://doi.org/10.1186/1756-9966-32-94
35. Worm, J. DNA methylation: an epigenetic pathway to cancer and a promising target for anticancer therapy / J. Worm, P. Guldberg // J. Oral Pathol. Med. - 2002. - Vol. 31, N 8. - P. 443-449. https://doi.org/10.1034/j.1600-0714.2002.00034.x
36. Метилирование гена RUNX3 как фактор прогноза при раке мочевого пузыря без мышечной инвазии / М. П. Смаль [и др.]// Докл. Нац. акад. наук Беларуси. - 2015. - Т. 59, № 5. - С. 85-90.
37. Мутации гена ТР53 и их прогностическая значимость при раке мочевого пузыря / М. П. Смаль [и др.]// Молекуляр. медицина. - 2015. - № 6. - С. 26-32.